Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 521,115 shares, an increase of 28.0% from the January 15th total of 407,278 shares. Currently, 3.2% of the company’s shares are sold short. Based on an average trading volume of 85,589 shares, the days-to-cover ratio is presently 6.1 days. Based on an average trading volume of 85,589 shares, the days-to-cover ratio is presently 6.1 days. Currently, 3.2% of the company’s shares are sold short.

Analyst Ratings Changes

A number of research firms have weighed in on LYEL. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price target for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lyell Immunopharma presently has an average rating of “Hold” and an average target price of $45.00.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $25.38 on Wednesday. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The stock has a market capitalization of $539.07 million, a P/E ratio of -1.10 and a beta of -0.14. The company’s fifty day moving average is $27.86 and its two-hundred day moving average is $20.03.

Insider Activity at Lyell Immunopharma

In other news, COO Stephen J. Hill sold 1,236 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $28,910.04. Following the sale, the chief operating officer owned 17,795 shares of the company’s stock, valued at approximately $416,225.05. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary K. Lee sold 1,671 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $39,084.69. Following the transaction, the insider owned 16,938 shares of the company’s stock, valued at approximately $396,179.82. This represents a 8.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 11,310 shares of company stock valued at $264,285. 22.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Clarius Group LLC grew its stake in shares of Lyell Immunopharma by 4.3% during the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock worth $324,000 after purchasing an additional 820 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after purchasing an additional 5,913 shares during the period. BBR Partners LLC purchased a new stake in Lyell Immunopharma during the fourth quarter worth about $210,000. ExodusPoint Capital Management LP acquired a new position in Lyell Immunopharma during the fourth quarter worth about $262,000. Finally, Marshall Wace LLP purchased a new position in Lyell Immunopharma in the second quarter valued at about $94,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.